Cargando…
New treatments for the mucopolysaccharidoses: from pathophysiology to therapy
Enzyme replacement therapy is currently considered the standard of care for the treatment of mucopolysaccharidoses (MPS) type I, II, VI, and IV. This approach has shown substantial efficacy mainly on somatic symptoms of the patients, but no benefit was found for other clinical manifestations, such a...
Autores principales: | Fecarotta, Simona, Gasperini, Serena, Parenti, Giancarlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238257/ https://www.ncbi.nlm.nih.gov/pubmed/30442204 http://dx.doi.org/10.1186/s13052-018-0564-z |
Ejemplares similares
-
Pathogenesis of Mucopolysaccharidoses, an Update
por: Fecarotta, Simona, et al.
Publicado: (2020) -
Cathepsins in the Pathophysiology of Mucopolysaccharidoses: New Perspectives for Therapy
por: De Pasquale, Valeria, et al.
Publicado: (2020) -
Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses
por: Barone, Rita, et al.
Publicado: (2018) -
S1.2 The pediatrician and the early onset Pompe
disease
por: Fecarotta, Simona, et al.
Publicado: (2011) -
ENT and mucopolysaccharidoses
por: Bianchi, Pier Marco, et al.
Publicado: (2018)